Showing results (91-100 of 150) with videos related to

Sort By:
Pageof 15
Urologic Oncology|January 16, 2025
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancerSiamak Daneshmand, Ashish M Kamat, Neal D Shore, et al.
European Urology|November 9, 2019
Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancerAlfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2016
Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab ResistanceKatrien Berns, Amir Sonnenblick, Annemiek Gennissen, et al.
The New England Journal of Medicine|October 23, 2023
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial CarcinomaMichiel S van der Heijden, Guru Sonpavde, Thomas Powles, et al.
Lancet (London, England)|December 23, 2017
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Ignacio Durán, Michiel S van der Heijden, et al.
The New England Journal of Medicine|March 6, 2024
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial CancerThomas Powles, Begoña P Valderrama, Shilpa Gupta, et al.
European Urology Oncology|July 8, 2026
MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical TrialsJoyce Greidanus, Margriet C van Dijk-de Haan, Antonella Messina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2022
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA ExpressionCora N Sternberg, Daniel P Petrylak, Joaquim Bellmunt, et al.
The Journal of Clinical Investigation|October 1, 2024
Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancerXiaolin Zhu, Tatyanah Farsh, Daniël Vis, et al.
European Urology|August 14, 2022
Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder CancerAlberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al.
Pageof 15